Stay updated with breaking news from Cgt Catapult. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical trial accounting for 81% of trials in 2023 and 80% in 2022.
GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage 11th March 2021 GlaxoSmithKline (GSK) is set to leverage the Cell and Gene Therapy (CGT) Catapult’s facility in Stevenage to expand its own clinical trial manufacturing capacity for cell and gene therapy. GSK will use the Stevenage facility to perform GMP cell processing to accelerate its pipeline of cell and gene therapy for clinical trials and streamline technical transfer. “The UK already has significant capabilities in cell and gene therapy, and this agreement illustrates how strategic investments by GSK can...
German CDMO will build new manufacturing capabilities at CGT Catapult site - News - PharmaTimes